ConductScience.org, home
hypertensive disorder
API referenceFor AI assistants

Disease · MONDO_0005044

Comparisons in its trials305

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

1 to 20 of 305

Download this page as JSON
ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Caduet vs Usual Care: serious adverse events51 of 77922 of 6821,461NCT00407537Trial comparisons
Telmisartan 40mg and Amlodipine 10mg vs Telmisartan 80mg and Amlodipine 10mg: serious adverse events4 of 83813 of 6111,449NCT00624052Trial comparisons
Telmisartan 40mg and Amlodipine 5mg vs Telmisartan 80mg and Amlodipine 5mg: serious adverse events22 of 9766 of 3971,373NCT00614380Trial comparisons
Without Concomitant Drugs vs With Concomitant Drugs: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs.3 of 36015 of 8851,245NCT01107743Trial comparisons
Male vs Female: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender.7 of 45811 of 7871,245NCT01107743Trial comparisons
Without Hypertension vs With Hypertension: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension.0 of 818 of 1,2371,245NCT01107743Trial comparisons
Without Hypercholesterolemia vs With Hypercholesterolemia: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia.
0 of 1818 of 1,2271,245NCT01107743Trial comparisons
Without Complications vs With Complications: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications.5 of 56813 of 6771,245NCT01107743Trial comparisons
<65 Years vs >=65 Years: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age.5 of 37713 of 8681,245NCT01107743Trial comparisons
Without Angina Pectoris vs With Angina Pectoris: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris.18 of 1,0620 of 1831,245NCT01107743Trial comparisons
Without Familial Hypercholesterolemia vs With Familial Hypercholesterolemia: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Familial Hypercholesterolemia.
18 of 1,2310 of 141,245NCT01107743Trial comparisons
Without Hepatic Dysfunction vs With Hepatic Dysfunction: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hepatic Dysfunction.14 of 1,0872 of 1451,232NCT01107743Trial comparisons
Without Renal Dysfunction vs With Renal Dysfunction: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Renal Dysfunction.14 of 1,1232 of 1081,231NCT01107743Trial comparisons
<65 Years vs >=65 Years: Risk Factors for the Proportion of Responders for Hypertension -Age.347 of 365804 of 8371,202NCT01107743Trial comparisons
Male vs Female: Risk Factors for the Proportion of Responders for Hypertension -Gender.415 of 438736 of 7641,202NCT01107743Trial comparisons
Without Concomitant Drugs vs With Concomitant Drugs: Risk Factors for the Proportion of Responders for Hypertension -Concomitant Drugs.339 of 355812 of 8471,202NCT01107743Trial comparisons
Without Complications vs With Complications: Risk Factors for the Proportion of Responders for Hypertension -Complications.527 of 555624 of 6471,202NCT01107743Trial comparisons
Without Hepatic Dysfunction vs With Hepatic Dysfunction: Risk Factors for the Proportion of Responders for Hypertension -Hepatic Dysfunction.1,008 of 1,053131 of 1371,190NCT01107743Trial comparisons
Without Renal Dysfunction vs With Renal Dysfunction: Risk Factors for the Proportion of Responders for Hypertension -Renal Dysfunction.1,036 of 1,085102 of 1041,189NCT01107743Trial comparisons
Without Complications vs With Complications: Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Complications.482 of 492552 of 5651,057NCT01107743Trial comparisons

diseases-2026-09-18-0.1.0

Next page

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005044/comparisons

API referenceFor AI assistants